IL292161B2 - New methylquinazolinone derivatives - Google Patents

New methylquinazolinone derivatives

Info

Publication number
IL292161B2
IL292161B2 IL292161A IL29216122A IL292161B2 IL 292161 B2 IL292161 B2 IL 292161B2 IL 292161 A IL292161 A IL 292161A IL 29216122 A IL29216122 A IL 29216122A IL 292161 B2 IL292161 B2 IL 292161B2
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
formula
Prior art date
Application number
IL292161A
Other languages
Hebrew (he)
Other versions
IL292161A (en
IL292161B1 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL292161A publication Critical patent/IL292161A/en
Publication of IL292161B1 publication Critical patent/IL292161B1/en
Publication of IL292161B2 publication Critical patent/IL292161B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Harvester Elements (AREA)
  • Combines (AREA)

Claims (21)

292161/-27- Claims
1. The compound of formula (I) (I) or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein the compound is the compound of formula (I).
3. A compound according to claim 1 or 2, wherein the compound is the compound of formula (Ia). (Ia)
4. A compound according to claim 1 or 2, wherein the compound is the compound of formula (Ib). (Ib)
5. A process for the preparation of a compound according to any one of claims 1 to 4, comprising the reaction of a compound of formula (B1) 292161/-28- (B1) with a compound of formula (B2) (B2) in the presence of a base.
6. A compound according to any one of claims 1 to 4 when manufactured according to a process of claim 5.
7. A compound according to any one of claims 1 to 4 for use as therapeutically active substance.
8. A pharmaceutical composition comprising a compound according to any one of claims 1 to and a therapeutically inert carrier.
9. A compound according to any one of claims 1 to 4 for use in the treatment or prophylaxis of cancer.
10. A compound according to any one of claims 1 to 4 for use in the treatment or prophylaxis of thyroid cancer, colorectal cancer, brain cancer, melanoma or NSCLC.
11. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is the compound of formula (Ia). (Ia). 292161/-29-
12. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is the compound of formula (Ib). (Ib).
13. A compound or a pharmaceutically acceptable salt thereof according to claim 11 or 12 for use as therapeutically active substance.
14. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof according to claim 11 or 12 and a therapeutically inert carrier.
15. A compound or a pharmaceutically acceptable salt thereof according claim 11 or 12 for use in the treatment or prophylaxis of cancer.
16. A compound or pharmaceutically acceptable salt thereof according to claim 11 or 12 for use in the treatment or prophylaxis of thyroid cancer, colorectal cancer, brain cancer, melanoma or NSCLC.
17. A pharmaceutically acceptable salt of the compound of claim 1, 3 or 4.
18. A pharmaceutically acceptable salt according to claim 11 or 12 for use as therapeutically active substance.
19. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 1, 11 or 12 and a therapeutically inert carrier.
20. A pharmaceutically acceptable salt according to claim 11 or 12 for use in the treatment or prophylaxis of cancer.
21. A pharmaceutically acceptable salt according to claim 11 or 12 for use in the treatment or prophylaxis of thyroid cancer, colorectal cancer, brain cancer, melanoma or NSCLC.
IL292161A 2019-12-10 2020-12-08 New methylquinazolinone derivatives IL292161B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10
PCT/EP2020/084976 WO2021116055A1 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Publications (3)

Publication Number Publication Date
IL292161A IL292161A (en) 2022-06-01
IL292161B1 IL292161B1 (en) 2024-12-01
IL292161B2 true IL292161B2 (en) 2025-04-01

Family

ID=68848113

Family Applications (2)

Application Number Title Priority Date Filing Date
IL316473A IL316473A (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives
IL292161A IL292161B2 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL316473A IL316473A (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Country Status (29)

Country Link
US (2) US12116349B2 (en)
EP (2) EP4483882A3 (en)
JP (2) JP7108146B2 (en)
KR (1) KR102836833B1 (en)
CN (2) CN114787156B (en)
AR (1) AR122351A1 (en)
AU (1) AU2020403443B2 (en)
CL (1) CL2022001529A1 (en)
CO (1) CO2022008968A2 (en)
CR (1) CR20220251A (en)
DK (1) DK4073065T3 (en)
ES (1) ES3023264T3 (en)
FI (1) FI4073065T3 (en)
HR (1) HRP20250418T1 (en)
HU (1) HUE071148T2 (en)
IL (2) IL316473A (en)
LT (1) LT4073065T (en)
MA (1) MA58087B1 (en)
MX (1) MX2022006783A (en)
PE (1) PE20221778A1 (en)
PH (1) PH12022551119A1 (en)
PL (1) PL4073065T3 (en)
PT (1) PT4073065T (en)
RS (1) RS66721B1 (en)
SI (1) SI4073065T1 (en)
TW (2) TWI877268B (en)
UA (1) UA128299C2 (en)
WO (1) WO2021116055A1 (en)
ZA (2) ZA202204675B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158541A1 (en) * 2019-12-10 2021-06-17 Cosimo Dolente New braf inhibitors as paradox breakers
SI4073065T1 (en) 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives
MX2022015703A (en) 2020-06-09 2023-01-24 Array Biopharma Inc 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders.
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
IL308015A (en) * 2021-06-09 2023-12-01 Hoffmann La Roche A combination of a specific BRAF inhibitor (paradox breaker) and a PD-1 spindle-binding antagonist for use in cancer treatment
CN117642166A (en) * 2021-06-09 2024-03-01 中外制药株式会社 Combination therapies for cancer treatment
JP2024522603A (en) * 2021-06-09 2024-06-21 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Novel solid form of (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
EP4378478A4 (en) 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
IL312171A (en) 2021-11-04 2024-06-01 Hoffmann La Roche Novel use of quinazolinone compound for the treatment of cancer
TW202409040A (en) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 Preparation and use of quinazolinone derivative as kinase inhibitor
JP2025537786A (en) 2022-11-18 2025-11-20 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Quinazolinone compounds as BRAF inhibitors for the treatment of advanced solid tumors or metastases - Patent Application 20070122997
EP4634171A1 (en) * 2022-12-15 2025-10-22 F. Hoffmann-La Roche AG Process for the preparation of a quinazolinone derivative
JP2025541200A (en) * 2022-12-15 2025-12-18 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Combination Therapies for Cancer Treatment
IL324898A (en) 2023-07-04 2026-01-01 Hoffmann La Roche New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]- 3-fluoro-pyrrolidine-1-sulfonamide
WO2025108405A1 (en) 2023-11-22 2025-05-30 西藏海思科制药有限公司 Preparation of quinazolinone derivative as kinase inhibitor, and use thereof
WO2025153057A1 (en) 2024-01-17 2025-07-24 海思科医药集团股份有限公司 Pharmaceutical composition comprising braf inhibitor and use of pharmaceutical composition in medicine
WO2026037755A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives
WO2026046946A1 (en) 2024-08-28 2026-03-05 F. Hoffmann-La Roche Ag New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (en) 2004-06-08 2010-03-10 有限会社コンペックス Method for producing sterilized fungus bed composition for straw cultivation and straw cultivation method
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP2010533729A (en) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド Compounds and methods for kinase regulation, and adaptations therefor
AU2009226136B2 (en) 2008-03-17 2013-08-15 Ambit Biosciences Corporation Quinazoline derivatives as RAF kinase modulators and methods of use thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
AR091876A1 (en) 2012-07-26 2015-03-04 Novartis Ag PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CA2882410A1 (en) 2012-09-19 2014-03-27 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
RU2015149937A (en) 2013-05-30 2017-07-06 Плексксикон Инк. COMPOUNDS FOR KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION
BR112017025045A2 (en) 2015-05-22 2018-08-07 Plexxikon Inc plx-8394 or plx-7904 for use in treating braf-v600 related diseases
PL3359541T3 (en) 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
RU2687107C1 (en) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Braf kinase inhibitor n-(3-(5-(4-chlorophenyl)-1h-pyrazolo[3,4-b]pyridin-3-carbonil)-2,4-difluorophenyl)propane-1-sulfonamide
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
TWI817018B (en) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 Compounds for the treatment of braf-associated diseases and disorders
SI4073065T1 (en) 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives
CA3158541A1 (en) * 2019-12-10 2021-06-17 Cosimo Dolente New braf inhibitors as paradox breakers
MX2022015703A (en) 2020-06-09 2023-01-24 Array Biopharma Inc 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders.
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
CN118561841A (en) 2020-12-18 2024-08-30 豪夫迈·罗氏有限公司 New aryl-pyrido-pyrimidin-one derivatives
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
KR20240115893A (en) 2021-12-08 2024-07-26 어레이 바이오파마 인크. N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroa Crystalline form of zetidine-1-sulfonamide

Also Published As

Publication number Publication date
CN114787156B (en) 2024-07-26
EP4073065B1 (en) 2025-02-19
BR112022011123A2 (en) 2022-08-23
LT4073065T (en) 2025-04-25
MA58087B1 (en) 2025-04-30
CN118791472A (en) 2024-10-18
PH12022551119A1 (en) 2023-08-23
TW202136245A (en) 2021-10-01
JP7108146B2 (en) 2022-07-27
ZA202204675B (en) 2022-12-21
HRP20250418T1 (en) 2025-06-06
AU2020403443A1 (en) 2022-05-12
SI4073065T1 (en) 2025-06-30
US20240174621A1 (en) 2024-05-30
KR102836833B1 (en) 2025-07-22
KR20220110554A (en) 2022-08-08
PE20221778A1 (en) 2022-11-16
EP4483882A3 (en) 2025-03-05
ES3023264T3 (en) 2025-05-30
IL316473A (en) 2024-12-01
PT4073065T (en) 2025-04-15
HUE071148T2 (en) 2025-08-28
IL292161A (en) 2022-06-01
RS66721B1 (en) 2025-05-30
MX2022006783A (en) 2022-07-11
CL2022001529A1 (en) 2023-02-10
PL4073065T3 (en) 2025-05-19
US20220298119A1 (en) 2022-09-22
EP4483882A2 (en) 2025-01-01
FI4073065T3 (en) 2025-04-16
AR122351A1 (en) 2022-09-07
TWI877268B (en) 2025-03-21
WO2021116055A1 (en) 2021-06-17
CA3162883A1 (en) 2021-06-17
NZ787393A (en) 2025-07-25
ZA202206923B (en) 2024-10-30
CR20220251A (en) 2022-07-11
US12116349B2 (en) 2024-10-15
CN114787156A (en) 2022-07-22
IL292161B1 (en) 2024-12-01
DK4073065T3 (en) 2025-04-22
TW202504895A (en) 2025-02-01
EP4073065A1 (en) 2022-10-19
TWI908405B (en) 2025-12-11
JP7802514B2 (en) 2026-01-20
JP2022531609A (en) 2022-07-07
AU2020403443B2 (en) 2023-02-23
UA128299C2 (en) 2024-05-29
CO2022008968A2 (en) 2022-07-19
JP2022124458A (en) 2022-08-25

Similar Documents

Publication Publication Date Title
IL292161B1 (en) New methylquinazolinone derivatives
ZA202308118B (en) Cdk inhibitor
JP2022124458A5 (en)
WO2024229444A3 (en) Pyrido[4,3-d]pyrimidine derivatives as mutant kras g12c inhibitors for the treatment of cancer
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
FI3788047T3 (en) SOLID FORM OF FGFT INHIBITOR AND METHODS FOR THEIR PREPARATION
MX2020013373A (en) Naphthyridinone compounds useful as t cell activators.
MX2020013817A (en) Substituted naphthyridinone compounds useful as t cell activators.
WO2023078333A8 (en) Substituted phenylpropionic acid derivative and use thereof
IL263110B (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
MX2019009187A (en) Quinazoline compound.
IL295418B1 (en) B-d-2'-deoxy-2'a-fluoro-2'-b-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
UA100972C2 (en) Antibacterial quinoline derivatives
WO2021009676A8 (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists
IL276194B2 (en) Compounds or pharmaceutical compositions comprising them for use in the treatment of paininhibiting
ZA202210640B (en) Deuterated oxophenylarsine compound and use thereof
IL276311B2 (en) Methyllactam ring compound and pharmaceutical use thereof
MX2014013056A (en) Antibacterial quinoline derivatives.
MX2009005981A (en) Antibacterial quinoline derivatives.
MY150411A (en) Antibacterial quinoline derivatives
WO2012143624A3 (en) Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same
NZ787393B2 (en) New methylquinazolinone derivatives
MX2021010970A (en) Heteroaryl derivatives and pharmaceutical composition comprising same as active ingredient.
WO2024249254A3 (en) Methods of using apol1 inhibitors
MY145940A (en) Antibacterial quinoline derivatives